IONS
Ionis Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.75 / 10
Netural
Analyst coverage is overwhelmingly bullish (100% Buy among 1 analyst), supported by a 66.7% historical win rate. Fund-flow data also show a good score of 7.8/10, with positive trends in block, small, and extra-large transactions, despite some negative medium/large flows. Together, these elements convey constructive sentiment, but the limited analyst base means consensus should be interpreted with caution. Overall, the stock enjoys supportive flows and opinions, adding a layer of optimism to the neutral fundamental and technical picture.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-06
InstitutionPiper Sandler
Times predicted3
Historical Win Rate66.7%
What is the analyst consensus for IONS?
- IONS holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.75/10 (Netural).
